ArticleCancer medicine2023

Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.

Ming-Hao Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.